// App-Quantinova.ai

BSH19‐PO‐170 : Apixaban Length‐Of‐Stay Pulmonary Embolism study ‐ Hospital Admissions (ALPHA‐PE)

Researchers

Presenter

  • R. Alikhan

Principal Investigators

  • S. Lister

  • C. Bomken

  • S. Chattree

  • C. Church

  • N. Smith

  • S. Shapiro

  • S. Grundy

  • J. Gordon

  • D. Sugrue

  • N. Hill

  • L. Howard

Medical Centers

  • Haematology, Cardiff and Vale university health board, Cardiff, UK

  • Health economics, Bristol‐Myers Squibb Ltd., Uxbridge

  • Haematology, North Tyneside General Hospital, North Shields

  • Rheumatology, Sunderland Royal Hospital, Sunderland, UK

  • Haematology, Queen Elizabeth University Hospital, Glasgow

  • Haematology, Birmingham Heartlands Hospital, Birmingham

  • Haematology,Oxford University Hospitals NHS Foundation Trust, NIHR Biomedical Research Centre,Oxford,Regno Unito

  • Medical Affairs, Bristol‐Myers Squibb Ltd., Uxbridge

  • Director

  • Medical Writer, HEOR Ltd., Cardiff

  • Outcomes Research, Bristol‐Myers Squibb Ltd., Uxbridge

  • Respiratory, Hammersmith Hospital, Imperial College NHS Trust, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Pulmonary/Respiratory Diseases

Disease

  • Pulmonary embolism

Biomarkers

  • N/A

Drug/Treatment

  • apixaban

  • Warfarin

  • Heparin

Outcome

  • N/A

Study Design

  • Observational

  • Multicenteric

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved